Pricing Log in Create free account

Gyre Therapeutics, Inc. (GYRE) vs Prime Medicine, Inc. (PRME)

Gyre Therapeutics, Inc. and Prime Medicine, Inc. are both Biotechnology companies. Gyre Therapeutics, Inc. and Prime Medicine, Inc. are of similar size ($678.6M and $654.8M). Gyre Therapeutics, Inc. grew revenue faster over the last twelve months: 10.7% against −17.9%. Gyre Therapeutics, Inc. has the higher net margin (−13.7% vs −4,613.1%) and the lower return on invested capital (−8.51% vs 0.00%). Across the 16 metrics below, Gyre Therapeutics, Inc. leads on 13 and Prime Medicine, Inc. on 3.

Valuation

Metric GYRE PRME Biotechnology median
P/E n/m n/m 8.50
P/S 5.26 150.99 9.71
P/B 4.29 15.45 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 4.66 127.65 9.21
Earnings yield (3.29%) (30.93%) (33.15%)
Free cash flow yield (1.16%) (25.50%) (25.50%)

Profitability

Metric GYRE PRME Biotechnology median
Gross margin 94.15% 100.00% 65.16%
Operating margin (10.53%) (4,824.94%) 0.00%
Net margin (13.73%) (4,613.11%) 0.00%
Free cash flow margin (6.12%) (3,850.92%) 0.00%
Return on equity (11.75%) (373.29%) (56.36%)
Return on assets (9.08%) (71.16%) (48.04%)
Return on invested capital (8.51%) 0.00% 0.00%

Growth

Metric GYRE PRME Biotechnology median
Revenue growth (TTM) 10.72% (17.90%) 6.02%
EPS growth (last fiscal year) (60.00%) 18.18% 30.26%
Revenue growth, 5-year CAGR 40.96% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GYRE PRME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.26 3.05 4.72
Net debt to EBITDA (3.74) 0.88 0.96

Dividend

Metric GYRE PRME Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GYRE PRME Biotechnology median
Market cap 678.62m 654.77m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack